2 completed. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow anabasum: new trials by email Literature Review of anabasum trials Research Report on anabasum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Lenabasum 20 mg, Lenabasum 5 mg, Placebo - Dermatomyositis | Phase 3 | Completed | Corbus Pharmaceuticals Inc. | 176 | 2018-12-17 | 2022-08-16 |
| JBT-101 in Systemic Lupus Erythematosus (SLE) JBT-101, Placebo - Systemic Lupus Erythematosus, SLE | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 109 | 2017-12-21 | 2026-05-06 |
Dermatomyositis (1) · Lupus Erythematosus, Systemic (1) · Musculoskeletal Diseases (1)
Corbus Pharmaceuticals Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1)
United States (2) · Bulgaria (1) · Canada (1) · Czechia (1) · Germany (1) · Hungary (1) · Italy (1) · Japan (1) · Poland (1) · South Korea (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Chester V Oddis, MD (1) · Meggan Mackay, M.D., M.S. (1) · Robert B. Zurier, M.D. (1) · Victoria P Werth, MD (1)
UM1AI110494 (1)